- Conditions: Asthma; Chronic Obstructive Pulmonary Disease (COPD)
Intervention: Drug: Albuterol Spiromax®
Sponsors: Teva Pharmaceutical Industries; Teva Pharmaceutical Industries
Not yet recruiting - verified May 2013 - Condition: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Drug: GFF MDI (PT003); Drug: GP MDI (PT001); Drug: FF MDI (PT005); Drug: Placebo
Sponsors: Pearl Therapeutics, Inc.; Pearl Therapeutics, Inc.
Not yet recruiting - verified May 2013 - Conditions: Lynch Syndrome; Colorectal Cancer
Interventions: Genetic: LS tumor screening; Genetic: Genetic testing; Behavioral: Genetic Counseling; Other: Biorepository; Behavioral: Questionnaire
Sponsors: Ohio State University Comprehensive Cancer Center; Ohio State University Comprehensive Cancer Center
Recruiting - verified May 2013 - Condition: Unresectable Pleural or Peritoneal Malignant Mesothelioma
Interventions: Drug: Tremelimumab; Drug: Placebo
Sponsors: MedImmune LLC; MedImmune LLC
Recruiting - verified May 2013 - Condition: Multiple Myeloma
Interventions: Drug: Carfilzomib; Drug: Bortezomib; Drug: Melphalan; Drug: Prednisone
Sponsors: Onyx Pharmaceuticals; Onyx Therapeutics, Inc.
Recruiting - verified May 2013 - Condition: Allergic Rhinitis
Interventions: Drug: BDP Nasal Aerosol; Drug: Placebo
Sponsors: Teva Pharmaceutical Industries; Teva Pharmaceutical Industries
Recruiting - verified May 2013 - Condition: Hyperlipidemia
Interventions: Drug: AMG 145; Other: Ezetimibe; Other: Placebo (administered subcutaneously); Other: Placebo (administered orally); Drug: Statin therapy
Sponsors: Amgen; Amgen
Recruiting - verified May 2013 - Condition: Alzheimer's Disease
Interventions: Drug: AC-1204; Drug: Placebo
Sponsors: Accera, Inc.; Accera, Inc.
Recruiting - verified May 2013 - Condition: Alzheimer's Disease
Interventions: Drug: MK-8931; Drug: Placebo
Sponsors: Merck; Merck
Recruiting - verified May 2013 - Condition: Multiple Myeloma
Interventions: Drug: Pomalidomide; Drug: Bortezomib; Drug: Dexamethasone
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified May 2013 - Conditions: Diabetes Mellitus, Non-Insulin-Dependent; High Risk for Cardiovascular Event
Interventions: Drug: Dapagliflozin 10 mg; Drug: Placebo tablet
Sponsors: AstraZeneca; AstraZeneca; Bristol-Myers Squibb; The TIMI Study Group; Hadassah Medical Organization
Recruiting - verified May 2013 - Condition: Breast Cancer
Interventions: Other: Educational DVD 1; Other: Educational DVD 2
Sponsors: Amgen; Amgen
Recruiting - verified May 2013 - Conditions: Rhinitis, Allergic, Perennial; Rhinitis, Allergic, Nonseasonal
Interventions: Biological: MK-8237 tablets; Biological: Placebo tablets; Drug: Rescue Medication: Self-Injectable Epinephrine; Drug: Rescue Medication: Loratadine tablets; Drug: Rescue Medication: Olopatadine ophthalmic drops; Drug: Rescue Medication: Mometasone furoate nasal spray
Sponsors: Merck; Merck
Recruiting - verified May 2013 - Condition: Cardiovascular Diseases
Interventions: Drug: Evacetrapib; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company; The Cleveland Clinic
Recruiting - verified May 2013 - Condition: Carcinoma, Non-Small-Cell Lung
Intervention: Drug: afatinib
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Available - verified May 2013 - Condition: Relapsing-remitting Multiple Sclerosis (RRMS)
Interventions: Drug: fingolimod; Drug: copaxone
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2013 - Condition: Polycythemia Vera
Interventions: Drug: ruxolitinib and HU-placebo; Drug: HU and ruxolitinib-placebo
Sponsors: Incyte Corporation; Incyte Corporation
Recruiting - verified May 2013 - Condition: Non-Small Cell Lung Cancer
Interventions: Drug: Custirsen + Docetaxel; Drug: Docetaxel
Sponsors: Teva Pharmaceutical Industries; Teva Pharmaceutical Industries
Recruiting - verified April 2013 - Condition: Asthma
Interventions: Drug: MK-1029; Drug: placebo; Drug: montelukast (ML)
Sponsors: Merck; Merck
Recruiting - verified May 2013 - Condition: Metastatic Pancreatic Cancer
Interventions: Drug: nab-paclitaxel; Drug: gemcitabine; Drug: placebo; Drug: M402
Sponsors: Momenta Pharmaceuticals, Inc.; Momenta Pharmaceuticals, Inc.
Recruiting - verified May 2013 - Condition: Asthma
Interventions: Drug: Fluticasone propionate DPI Dose 1; Drug: Fluticasone propionate DPI Dose 2; Drug: Fluticasone propionate DPI Dose 3; Drug: Fluticasone propionate DPI Dose 4; Other: Placebo DPI; Drug: Flovent Diskus 250 mcg
Sponsors: Teva Pharmaceutical Industries; Teva Pharmaceutical Industries
Recruiting - verified April 2013 - Condition: Chronic Lymphocytic Leukemia (CLL)
Interventions: Drug: Dinaciclib; Drug: Ofatumumab
Sponsors: Merck; Merck
Recruiting - verified May 2013 - Condition: Multiple Myeloma
Interventions: Drug: Carfilzomib plus dexamethasone; Drug: Velcade plus dexamethasone
Sponsors: Onyx Pharmaceuticals; Onyx Pharmaceuticals
Recruiting - verified May 2013 - Condition: Asthma
Interventions: Drug: Fluticasone Furoate; Drug: Fluticasone Propionate; Drug: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2013 - Condition: Schizophrenia
Interventions: Drug: PPM3 175 mg eq.; Drug: PPM3 263 mg eq.; Drug: PP3M 350 mg eq.; Drug: PP3M 525 mg eq.; Drug: Placebo (20% Intralipid emulsion)
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified April 2013 - Condition: Hematopoietic Neoplasm
Intervention: Drug: SAR302503
Sponsors: Sanofi; Sanofi
Recruiting - verified May 2013 - Condition: Schizophrenia
Interventions: Drug: PP3M 175 mg eq.; Drug: PP3M 263 mg eq.; Drug: PP3M 350 mg eq.; Drug: PP3M 525 mg eq.; Drug: Placebo (20% Intralipid); Drug: PP1M 50 mg eq.; Drug: PP1M 75 mg eq.; Drug: PP1M 100 mg eq.; Drug: PP1M 150 mg eq.
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified May 2013 - Condition: Asthma
Interventions: Drug: Placebo; Drug: Flovent Diskus; Drug: Fluticasone propionate DPI Dose 1; Drug: Fluticasone propionate DPI Dose 2; Drug: Fluticasone propionate DPI Dose 3; Drug: Fluticasone propionate DPI Dose 4
Sponsors: Teva Pharmaceutical Industries; Teva Pharmaceutical Industries; PPD
Recruiting - verified April 2013 - Condition: Asthma
Interventions: Drug: Mometasone Furoate/Formoterol MDI 100/5 mcg; Drug: Mometasone Furoate/Formoterol MDI 200/5 mcg; Drug: Mometasone Furoate MDI 100 mcg; Drug: Mometasone Furoate MDI 200 mcg; Drug: Albuterol 90 mcg /salbutamol 100 mcg HFA MDI; Drug: Prednisone/prednisolone
Sponsors: Merck; Merck
Recruiting - verified May 2013 - Condition: Depression Disorder, Major
Interventions: Drug: RO4995819; Drug: RO4995819; Drug: RO4995819; Drug: Placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013 - Condition: Epilepsy, Partial Seizures
Intervention: Drug: Pregabalin
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2013 - Condition: Small Cell Lung Carcinoma
Interventions: Biological: Ipilimumab; Biological: Placebo matching Ipilimumab; Drug: Etoposide; Drug: Cisplatin; Drug: Carboplatin
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified May 2013 - Condition: Asthma
Interventions: Drug: Placebo; Drug: Albuterol Spiromax®
Sponsors: Teva Pharmaceutical Industries; Teva Branded Pharmaceutical Products, R&D Inc.
Recruiting - verified May 2013 - Condition: Depression, Bipolar
Interventions: Drug: Placebo; Drug: Cariprazine; Drug: Cariprazine; Drug: Cariprazine
Sponsors: Forest Laboratories; Forest Laboratories; Gedeon Richter Ltd.
Recruiting - verified April 2013 - Condition: Major Depressive Disorder
Intervention: Drug: DVS SR
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2013 - Condition: Major Depressive Disorder
Interventions: Drug: Desvenlafaxine Succinate Sustained-Release; Drug: Desvenlafaxine Succinate Sustained-Release; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2013 - Condition: Non-Small Cell Lung Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: Standard of care treatment
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013 - Conditions: Primary Myelofibrosis; Post Essential Thrombocythemia-myelofibrosis; Post Polycythemia Vera-myelofibrosis
Intervention: Drug: Ruxolitinib (INCB018424)
Sponsors: Incyte Corporation; Incyte Corporation
Recruiting - verified May 2013 - Condition: Advanced Liposarcoma or Leiomyosarcoma
Interventions: Drug: Trabectedin; Drug: Dacarbazine
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC; Pharma Mar, S.A.U.
Recruiting - verified May 2013 - Condition: Prostate Cancer Metastatic
Interventions: Biological: PROSTVAC-V; Biological: PROSTVAC-F; Drug: GM-CSF; Other: GM-CSF Placebo; Biological: Placebo
Sponsors: BN ImmunoTherapeutics; BN ImmunoTherapeutics
Recruiting - verified February 2013 - Conditions: Diffuse Large B-cell Lymphoma; de Novo DLBCL; DLBCL Transformed From Indolent Lymphoma; Follicular Grade 3 Lymphoma
Interventions: Drug: Pixantrone + Rituximab; Drug: Gemcitabine + Rituximab
Sponsors: Cell Therapeutics; Cell Therapeutics
Recruiting - verified April 2013 - Condition: Smoking Cessation
Interventions: Drug: Varenicline 1mg BID; Drug: Varenicline 0.5mg BID; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Condition: Warfarin Therapy
Intervention: Device: Warfarin GenoSTAT Test
Sponsors: Iverson Genetic Diagnostics, Inc.; Iverson Genetic Diagnostics, Inc.
Recruiting - verified May 2013 - Conditions: Left Ventricular Dysfunction; Heart Failure
Interventions: Device: CardioFit® System; Other: Standard of Care
Sponsors: BioControl Medical; BioControl Medical
Recruiting - verified May 2013 - Condition: Colorectal Cancer
Interventions: Biological: Imprime PGG + cetuximab; Drug: Cetuximab
Sponsors: Biothera; Biothera
Recruiting - verified May 2013 - Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast CancerConditions: Estrogen Receptor-negative Breast Cancer; Estrogen Receptor-positive Breast Cancer; HER2-positive Breast Cancer; Progesterone Receptor-negative Breast Cancer; Progesterone Receptor-positive Breast Cancer; Recurrent Breast Cancer; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer
Interventions: Drug: doxorubicin hydrochloride; Drug: docetaxel; Drug: cyclophosphamide; Biological: trastuzumab; Drug: paclitaxel; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013 - Conditions: Recurrent Melanoma; Stage IIIB Melanoma; Stage IIIC Melanoma; Stage IV Melanoma
Interventions: Biological: ipilimumab; Biological: recombinant interferon alfa-2b; Other: pharmacological study; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified April 2013 - Conditions: Dysphagia; Lung Cancer; Pain
Interventions: Drug: Manuka honey; Drug: chemotherapy; Other: questionnaire administration; Procedure: adjuvant therapy; Procedure: assessment of therapy complications; Procedure: quality-of-life assessment; Procedure: standard follow-up care; Radiation: radiation therapy
Sponsors: Radiation Therapy Oncology Group; Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified April 2013 - Condition: Herpes Zoster
Interventions: Biological: V212; Biological: Placebo
Sponsors: Merck; Merck
Recruiting - verified May 2013 - Condition: Bipolar Disorder, Pediatric
Interventions: Drug: asenapine; Drug: Placebo to match asenapine; Drug: Rescue medication
Sponsors: Merck; Merck
Recruiting - verified May 2013 - Condition: Fibromyalgia
Interventions: Drug: Duloxetine; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013 - Condition: Lymphoma, Follicular
Interventions: Biological: Ofatumumab; Biological: Rituximab
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2013 - Condition: Relapsed/Refractory Multiple Myeloma
Interventions: Drug: plitidepsin + dexamethasone; Drug: dexamethasone
Sponsors: PharmaMar; PharmaMar
Recruiting - verified March 2013 - Condition: Heart Failure With Reduced Ejection Fraction
Interventions: Drug: LCZ696 200 mg BID; Drug: Enalapril 10 mg BID
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2013 - Conditions: Breast Cancer; Cardiac Toxicity
Interventions: Drug: Coreg CR®; Drug: lisinopril; Other: placebo
Sponsors: University of South Florida; University of South Florida; National Cancer Institute (NCI)
Recruiting - verified January 2013 - Conditions: Distal Urethral Cancer; Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter; Proximal Urethral Cancer; Recurrent Bladder Cancer; Recurrent Prostate Cancer; Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter; Recurrent Urethral Cancer; Stage IV Bladder Cancer; Stage IV Prostate Cancer; Transitional Cell Carcinoma of the Bladder; Urethral Cancer Associated With Invasive Bladder Cancer
Interventions: Drug: gemcitabine hydrochloride; Drug: cisplatin; Other: placebo; Biological: bevacizumab; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013 - Condition: Severe Thrombocytopenia
Intervention: Drug: oprelvekin
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Condition: Brain Injuries
Intervention: Drug: NNZ-2566
Sponsors: Neuren Pharmaceuticals Limited; Neuren Pharmaceuticals Limited
Recruiting - verified May 2013 - Condition: Meningococcal Disease
Intervention: Biological: Meningococcal vaccine GSK134612
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013 - Conditions: Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer
Interventions: Drug: sunitinib malate; Other: placebo; Procedure: quality-of-life assessment; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013 - Conditions: Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma
Interventions: Drug: melphalan; Drug: prednisone; Drug: thalidomide; Drug: lenalidomide
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013 - Condition: Endometrial Cancer
Interventions: Drug: cisplatin; Radiation: brachytherapy; Radiation: external beam radiation therapy
Sponsors: Gynecologic Oncology Group; Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2013 - Conditions: Neoplasms, Breast; Breast Cancer
Interventions: Drug: Lapatinib; Biological: Trastuzumab
Sponsors: GlaxoSmithKline; GlaxoSmithKline; North Central Cancer Treatment Group; National Cancer Institute (NCI); Breast International Group; NCIC Clinical Trials Group
Recruiting - verified May 2013 - Conditions: Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Cancer; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer
Interventions: Biological: ziv-aflibercept; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013 - Condition: Lymphoma, B-Cell
Interventions: Drug: inotuzumab ozogamicin; Drug: inotuzumab ozogamicin; Drug: inotuzumab ozogamicin
Sponsors: Pfizer; Pfizer; UCB, Inc.
Recruiting - verified May 2013 - Conditions: Cervical Adenocarcinoma; Cervical Adenosquamous Cell Carcinoma; Cervical Squamous Cell Carcinoma; Stage IB Cervical Cancer; Stage IIA Cervical Cancer; Stage IIB Cervical Cancer; Stage III Cervical Cancer; Stage IVA Cervical Cancer
Interventions: Drug: cisplatin; Drug: tirapazamine
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI); NCIC Clinical Trials Group
Recruiting - verified May 2013 - Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Drug: paclitaxel; Drug: paclitaxel poliglumex; Other: clinical observation
Sponsors: Gynecologic Oncology Group; Gynecologic Oncology Group; National Cancer Institute (NCI); CTI
Recruiting - verified May 2013

Clinical Trial Locations 